The goals of the Oral Cancer Research Program (OCRPP) at The Ohio State University are to: 1) enhance and facilitate investigations of those interactions between human cells of the oral cavity and tobacco by- products that lead to adverse biological responses; 2) coordinate activities that will utilize the information obtained from these interactions, at malignant oral lesions; and, 3) promote and develop research that will determine the efficacy of control and intervention strategies. Established investigators in the Oral Cancer Research Program Project """"""""Molecular Events in the Progress/Prevention of Oral Cancer"""""""" are concentrating their efforts in five major areas of research (Research Projects) to address this central theme. Research Project 1 (Carcinogen/Oxidant Synergism in Oral Cancer Initiation is focussing on initiating events in oral cancer. They will determine the metabolic fate of tobacco-associated carcinogens (TAC) in oral mucosal cells and how the metabolism of these compounds may be modified by ethanol. Project 1 will also explore the ability of oral mucosal cells to respond to physiologically relevant concentrations of reactive oxygen species. The genetic events leading to the establishment of premalignant and malignant lesions will be studied by Research Projects 2 and 3. Research Project 2 (Role of G/1 Phase Regulatory Genes and Identification of Differentially Expressed Novel Genes in Premalignant Oral Lesions) will evaluate those genes more closely associated with aberrant cell proliferation. Research Project 3 (Inactivation of the TGF-beta Receptor Complex in Oral Cancer Development) will study the loss of control of cell cycle proliferation by evaluating the effect of gene alterations (mutations, deletions, methylation) on the TGF-beta receptor complex (i.e., protein binding, kinase activity, and modification of specific downstream substrates). Research Project 4 (Molecular Mechanisms in Conversion of Cells in Oral Tissues from Normal to Premalignant and from Premalignant to Malignant) will explore those conditions involved in the transformation of normal cells into premalignant cells by TACs and the conversion of premalignant oral dysplasias into squamous cell carcinomas. In concert with Research Projects 2 and 3, the cells transformed in vitro by TAC, or concerted to malignancy by TAC, will be examined to determine if the same changes occur in cell cycle regulatory genes and the TGFbeta receptor complex as are found in premalignant and malignant tissues form patients. The rationale for the studies in Research Projects 1, 2, 3, and 4 is to provide information on those premalignant to the malignant stage. This information will be employed by Research Project 3 (Chemoprevention of Premalignant and Malignant Oral Tumors) which will develop strategies for intervention and preventive measures whereby the cytotoxic or genetic damage manifested by tobacco-related products is inhibited or modified and progression of dysplastic lesions to malignancy is prevented. This involves both natural and synthetic chemicals that affect the activation and detoxification of TAC and that interact with and modify the function of critical cellular genes or gene products that are responsible for the generation and maintenance of premalignant dysplasias and the conversion of these dysplasia into malignant oral cancers. In summary, the major thrust of the Program Project is to investigate the multiple genetic pathways in the loss of regulatory control of cell proliferation, differentiation, and apoptosis. With this information, we should be able to determine which chemopreventative agents will best intervene in the early stages of the cascade of events leading to oral cancer and by understanding the nature of the molecular changes occurring in the early stages of disease, we can develop strategies directed towards the modulation of those events that are specifically involved in the process.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Program Projects (P01)
Project #
5P01DE012704-04
Application #
6379849
Study Section
Special Emphasis Panel (ZDE1-PW (18))
Program Officer
Shirazi, Yasaman
Project Start
1998-09-15
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
4
Fiscal Year
2001
Total Cost
$815,701
Indirect Cost
Name
Ohio State University
Department
Administration
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Giannini, Peter J; Morse, Mark A; Weghorst, Christopher M et al. (2008) Functional Activities and Immunohistochemical Cellular Distribution of Glutathione S-Transferases in Normal, Dysplastic, and Squamous Cell Carcinoma Human Oral Tissues. Clin Med Oncol 2:159-168
Wang, Dian; Grecula, John C; Gahbauer, Reinhard A et al. (2006) p16 gene alterations in locally advanced squamous cell carcinoma of the head and neck. Oncol Rep 15:661-5
Sedghizadeh, Parish P; Mallery, Susan R; Thompson, Sarah J et al. (2006) Expression of the serine protease DESC1 correlates directly with normal keratinocyte differentiation and inversely with head and neck squamous cell carcinoma progression. Head Neck 28:432-40
Han, ChunHua; Ding, Haiming; Casto, Bruce et al. (2005) Inhibition of the growth of premalignant and malignant human oral cell lines by extracts and components of black raspberries. Nutr Cancer 51:207-17
Pasche, Boris; Knobloch, Thomas J; Bian, Yansong et al. (2005) Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 294:1634-46
Ding, Haiming; Han, Chunhua; Zhu, Jiuxiang et al. (2005) Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113:803-10
Mallery, Susan R; Morse, Mark A; Wilson, Ralph F et al. (2003) AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion. J Cell Biochem 89:133-43
Wilson, Ralph F; Morse, Mark A; Pei, Ping et al. (2003) Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res 23:1289-95
Ding, Haiming; Han, Chunhua; Gibson-D'Ambrosio, Ruth et al. (2003) Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Int J Cancer 107:830-6
Smiraglia, D J; Smith, L T; Lang, J C et al. (2003) Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40:25-33

Showing the most recent 10 out of 24 publications